159
Participants
Start Date
February 28, 2014
Primary Completion Date
December 31, 2024
Study Completion Date
December 31, 2024
5 mg Prednisone
Subjects will remain on daily prednisone dose of 5 mg
0 mg Prednisone
Subjects will taper their prednisone dose from 5 mg per day to 0 mg per day
University of Pittsburgh, Pittsburgh
University of Pennsylvania, Philadelphia
Cleveland Clinic, Cleveland
Mayo Clinic, Rochester
University of Kansas Medical Center, Kansas City
University of Utah, Salt Lake City
Brigham and Women's Hospital, Boston
St. Joseph's Healthcare, Hamilton
Mount Sinai Hospital, Toronto
National Heart, Lung, and Blood Institute (NHLBI)
NIH
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Office of Rare Diseases (ORD)
NIH
National Center for Advancing Translational Sciences (NCATS)
NIH
Rare Diseases Clinical Research Network
NETWORK
University of Pennsylvania
OTHER